Related Experiment Video
Updated: Jan 3, 2026
04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
932
The Progressive Supranuclear Palsy: Past and Present Aspects.
Theodore P Parthimos1, Kleopatra H Schulpis2
13rd Age Day Care Center IASIS, Glyfada, Greece.
Clinical Gerontologist
|November 23, 2019
Summary
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by motor, cognitive, and behavioral impairments. Early diagnosis and comprehensive assessments are crucial for managing PSP and improving patient quality of life.
Area of Science:
- Neuroscience
- Neurology
Background:
- Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease.
- New diagnostic criteria and distinct clinical phenotypes are emerging.
- Understanding PSP's multifaceted nature is crucial for patient care.
Purpose of the Study:
- To review current knowledge on progressive supranuclear palsy (PSP).
- To describe the cognitive and behavioral profile of PSP patients.
- To explore underlying pathology, genetics, and treatment options.
Main Methods:
- Systematic literature search of Medline and Scopus databases.
- Inclusion of English-language articles only.
- Review of clinical characteristics, cognitive impairments, and behavioral symptoms.
Main Results:
- Common PSP symptoms include falls, gaze palsy, parkinsonism, and pseudobulbar palsy.
- Key cognitive deficits involve executive dysfunction and verbal fluency.
- Apathy and impulsivity significantly impact patients and caregivers.
Conclusions:
- PSP is characterized by tau neuropathology.
- Impairments affect daily living; neuropsychological assessments are vital.
- Pharmacological and non-pharmacological treatments can improve quality of life.
More Related Videos
Related Concept Videos
01:15Parkinson's Disease: Overview
1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
01:24Parkinson's Disease: Treatment
905
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
905
01:37Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
01:32Postsynaptic Potential (PSP)
4.6K
Postsynaptic potential (PSP) refers to a change in the electrical potential of a neuron when neurotransmitters released by presynaptic neurons bind to postsynaptic receptors. This potential can either be excitatory, leading to depolarization and ultimately action potential generation, or inhibitory, leading to hyperpolarization and suppression of the postsynaptic neuron.
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
4.6K
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
01:20Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K